parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in corticotrophs	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	24 Parkinson's papers of 1,244	0.58
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 5747

receipt 5755: ASCL1 in dopamine neurons, braak

power: full sample -0.18 (p 0.487, n 18), 95% CI -0.59 to +0.32. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.12 (p 0.640, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.671, n 18). could be the mix.
skeptic: leave-one-out range -0.33 to -0.05, sign flips 0; without severely affected donors -0.18 (p 0.487, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ASCL1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5754: ASCL1 in oligodendrocytes, braak

power: full sample -0.20 (p 0.429, n 18), 95% CI -0.61 to +0.30. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.19 (p 0.455, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.27 (p 0.281, n 18). could be the mix.
skeptic: leave-one-out range -0.29 to -0.08, sign flips 0; without severely affected donors -0.20 (p 0.429, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ASCL1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts